Journal of Isfahan Medical School

Journal of Isfahan Medical School

Drug Resistance to Antifungal Drugs: A Review Article

Document Type : Review Article

Authors
Mahrokh Marzi 1
Elham Zarenezhad 2
1 Researcher at Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
2 Associate Professor, Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
10.48305/jims.v43.i847.2002
Abstract
Background: Fungal infections are one of the main causes of mortality from infectious diseases worldwide. Candida species are among the most common causes of invasive fungal diseases, and Candida albicans is the leading cause of invasive candidiasis. Considering that fungi, like their human hosts, are eukaryotes, the number of unique molecular targets that can be utilized for the development of antifungal drugs remains limited. The aim of this study is to review the current status of antifungal drugs and potential new therapeutic approaches, as the increasing prevalence of fungal species resistant to antifungal drugs, both intrinsically and acquired, is a serious threat to public health.
Methods: In this study, various databases including Web of Science, Scopus, PubMed, and Google Scholar were evaluated with keywords including Mycoses, Drug resistance, Candida albicans, Therapeutics, and related articles were reviewed in the time period 2019-2025.
FindingsThis review addresses some of the most promising therapeutic strategies that may help combat antifungal resistance, including combination therapy, targeting fungal virulence features, and modulating host immunity.
Conclusion: Overall, a comprehensive understanding of the mechanistic principles governing antifungal drug resistance is essential for the development of novel therapies to combat current and emerging fungal threats.

Highlights

Mahrokh Marzi: Google Scholar

Elham Zarenezhad: Google Scholar

Keywords
Mycoses
Drug resistance s
Candida albicans
Therapeutics

Subjects

1.     Schmiedel Y, Zimmerli S. Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia. Swiss Med Wkly 2016; 146: w14281.
2.     Perfect JR. The antifungal pipeline: a reality check. Nat Rev Drug Discov 2017; 16(9): 603-16.
3.     Bajpai VK, Khan I, Shukla S, Kumar P, Rather IA, Park Y-H, et al. Invasive fungal infections and their epidemiology: Measures in the clinical scenario. Biotechnology and Bioprocess Engineering 2019; 24: 436-444
4.     Zarenezhad E, Ghasemian A, Iraji A, Kazemi M, Haghjoo E. Synthesis of 1-aryl 4-phenyl 1, 2, 3-triazols and Investigating anti-fungal and anti-bacterial activity in in vitro زonditions [in Persian]. Med Sci 2025; 34(1): 46-55.
5.     Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010; 36(1): 1-53.
6.     Enoch DA, Yang H, Aliyu SH, Micallef C. The changing epidemiology of invasive fungal infections. Methods Mol Biol 2017; 1508: 17-65.
7.     Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997–2016.  Open forum infectious diseases; Oxford University Press US ; 2019:.
8.     Rad MNS, Behrouz S, Mohammad-Javadi M, Zarenezhad E. Synthesis of fish scale derived hydroxyapatite silica propyl bis aminoethoxy ethane cuprous complex (HASPBAEECC) as a novel hybrid nano-catalyst for highly efficient synthesis of new benzimidazole-1, 2, 3-triazole hybrid analogues as antifungal agents. Mol Divers 2022; 26(5): 2503-21.
9.     Lockhart SR. Candida auris and multidrug resistance: defining the new normal. Fungal Genet Biol 2019; 131: 103243.
10.  Rautenbach M, Troskie AM, Vosloo JA. Antifungal peptides: To be or not to be membrane active. Biochimie 2016; 130: 132-45.
11.  Lee Y, Puumala E, Robbins N, Cowen LE. Antifungal drug resistance: molecular mechanisms in Candida albicans and beyond. Chem Rev 2020; 121(6): 3390-411.
12.  Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH. An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 2010; 9(9): 19-27
13.  Anderson TM, Clay MC, Cioffi AG, Diaz KA, Hisao GS, Tuttle MD, et al. Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat Chem Biol 2014; 10(5): 400-6.
14.  Afsarian MH, Farjam M, Zarenezhad E, Behrouz S, Rad MNS. Synthesis, antifungal evaluation and molecular docking studies of some tetrazole derivatives. Acta Chim Slov 2019; 66(4): 874-87.
15.  Marzi M, Farjam M, Kazeminejad Z, Shiroudi A, Kouhpayeh A, Zarenezhad E. A recent overview of 1, 2, 3‐triazole‐containing hybrids as novel antifungal agents: Focusing on synthesis, mechanism of action, and structure‐activity relationship (SAR). Journal of Chemistry 2022; 2022(1): 7884316.
16.  Kazeminejad Z, Marzi M, Shiroudi A, Kouhpayeh SA, Farjam M, Zarenezhad E. Novel 1, 2, 4‐Triazoles as Antifungal Agents. BioMed Research International. 2022;2022(1):4584846.
17.  Isticato R, Ricca E. Spore surface display. Biomed Res Int 2016; 2022: 349-66.
18.  Behrouz S, Rad MNS, Rostami S, Behrouz M, Zarehnezhad E, Zarehnezhad A. Design, synthesis, and biological activities of novel azole-bonded β-hydroxypropyl oxime O-ethers. Mol Divers 2014; 18(4): 797-808.
19.  Patil A, Majumdar S. Echinocandins in antifungal pharmacotherapy. J Pharm Pharmacol 2017; 69(12): 1635-60.
20.  Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362(9390): 1142-51.
21.  Cui X, Wang L, Lue Y, Yue C. Development and research progress of anti-drug resistant fungal drugs. J Infect Public Health 2022; 15(9): 986-1000.
22.  Denning DW. Antifungal drug resistance: an update. Eur J Hosp Pharm 2022; 29(2): 109-12.
23.  Spitzer M, Robbins N, Wright GD. Combinatorial strategies for combating invasive fungal infections. Virulence 2017; 8(2): 169-85.
24.  Onyewu C, Blankenship JR, Del Poeta M, Heitman J. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother 2003; 47(3): 956-64.
25.  Costanzo M, VanderSluis B, Koch EN, Baryshnikova A, Pons C, Tan G, et al. A global genetic interaction network maps a wiring diagram of cellular function. Science 2016; 353(6306): aaf1420.
26.  Costanzo M, Baryshnikova A, Myers CL, Andrews B, Boone C. Charting the genetic interaction map of a cell. Curr Opin Biotechnol 2011; 22(1): 66-74.
27.  Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, Sevier CS, et al. The genetic landscape of a cell. Science 2010; 327(5964): 425-31
28.  Nishikawa JL, Boeszoermenyi A, Vale-Silva LA, Torelli R, Posteraro B, Sohn Y-J, et al. Inhibiting fungal multidrug resistance by disrupting an activator–mediator interaction. Nature 2016; 530(7591): 485-9.
29.  Whitesell L, Robbins N, Huang DS, McLellan CA, Shekhar-Guturja T, LeBlanc EV, et al. Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus. Nat Commun 2019; 10(1): 402.
30.  Caplan T, Lorente-Macías Á, Stogios PJ, Evdokimova E, Hyde S, Wellington MA, et al. Overcoming fungal echinocandin resistance through inhibition of the non-essential stress kinase Yck2. Cell Chem Biol 2020; 27(3): 269-82. e5.
31.  Baltz RH. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr Opin Chem Biol 2009; 13(2): 144-51.
32.  Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 2007; 3(9): 541-8.
33.  Gauwerky K, Borelli C, Korting HC. Targeting virulence: a new paradigm for antifungals. Drug Discov Today 2009; 14(3-4): 214-22.
34.  Noble SM, Gianetti BA, Witchley JN. Candida albicans cell-type switching and functional plasticity in the mammalian host. Nat Rev Microbio 2017; 15(2): 96-108.
35.  Noble SM, French S, Kohn LA, Chen V, Johnson AD. Systematic screens of a Candida albicans homozygous deletion library decouple morphogenetic switching and pathogenicity. Nat Genet 2010; 42(7): 590-8.
36.  Shapiro RS, Uppuluri P, Zaas AK, Collins C, Senn H, Perfect JR, et al. Hsp90 orchestrates temperature-dependent Candida albicans morphogenesis via Ras1-PKA signaling. Curr Biol 2009; 19(8): 621-9.
37.  Fortwendel JR, Juvvadi PR, Rogg LE, Asfaw YG, Burns KA, Randell SH, et al. Plasma membrane localization is required for RasA-mediated polarized morphogenesis and virulence of Aspergillus fumigatus. Eukaryot Cell 2012; 11(8): 966-77.
38.  Hast MA, Nichols CB, Armstrong SM, Kelly SM, Hellinga HW, Alspaugh JA, et al. Structures of Cryptococcus neoformans protein farnesyltransferase reveal strategies for developing inhibitors that target fungal pathogens. J Biol Chem 2011; 286(40): 35149-62.
39.  Song JL, White TC. RAM2: an essential gene in the prenylation pathway of Candida albicans. Microbiology (Reading) 2003; 149(1): 249-59.
40.  Vallim MA, Fernandes L, Alspaugh JA. The RAM1 gene encoding a protein-farnesyltransferase β-subunit homologue is essential in Cryptococcus neoformans. Microbiology (Reading) 2004; 150(6): 1925-35.
41.  Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, Galli C, et al. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 2005; 202(5): 597-606.
42.  Bromuro C, Romano M, Chiani P, Berti F, Tontini M, Proietti D, et al. Beta-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine 2010; 28(14): 2615-23.
Pietrella D, Rachini A, Torosantucci A, Chiani P, Brown AJ, Bistoni F, et al. A β-glucan-conjugate vaccine and anti-β-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. Vaccine 2010; 28(7): 1717-25.
Journal of Isfahan Medical School
Volume 43, Issue 847
3rd Week, March
March and April 2026
Pages 2002-2010

  • Receive Date 17 April 2025
  • Accept Date 10 December 2025